肠溶霉酚酸钠治疗非感染性中间葡萄膜炎:一项前瞻性、对照、随机、开放标签、提前终止的多中心试验结果
这项前瞻性随机对照多中心试验纳入41例非感染性中间葡萄膜炎患者,比较泼尼松龙联合肠溶霉酚酸钠与泼尼松龙单药治疗。联合治疗组首次复发率40.9%,低于对照组的78.9%(p=0.03);15个月无复发生存概率联合组52.9%,对照组19.7%(p=0.01)。作者认为肠溶霉酚酸钠可被视为预防慢性中间葡萄膜炎复发的有效且耐受良好的免疫抑制药物。
要点
- 联合组首次复发9例(40.9%),对照组15例(78.9%),差异有统计学意义(p=0.03)。
- 15个月无复发生存概率联合组52.9%,对照组19.7%(p=0.01)。
- 仅1例因肝酶升高停用肠溶霉酚酸钠,试验期间未出现安全性顾虑。
核心结论
- 作者认为肠溶霉酚酸钠可被视为预防慢性中间葡萄膜炎复发的有效且耐受良好的免疫抑制药物。
研究设计与样本
- 开放标签、前瞻性、对照、随机、多中心试验,患者按1:1随机分为泼尼松龙联合肠溶霉酚酸钠组或泼尼松龙单药对照组。
- 对照组6个月内复发者转入交叉组(泼尼松龙联合肠溶霉酚酸钠),最长治疗15个月,主要终点为治疗组与对照组首次复发时间。
- 共分析8个中心的41例患者,治疗组22例,对照组19例。
主要发现
- 治疗组首次复发9例(40.9%),对照组15例(78.9%),p=0.03。
- 治疗组首次复发中位时间>15个月,对照组2.8个月,p=0.07。
- 第15个月无复发生存概率治疗组估计为52.9%,对照组19.7%,p=0.01。
- 15例患者转入交叉组,其中仅4例出现第二次复发。
- 试验期间未出现安全性顾虑,仅1例因肝酶升高停用肠溶霉酚酸钠。
临床怎么用
- 原文结论认为肠溶霉酚酸钠可被视为预防慢性中间葡萄膜炎复发的有效且耐受良好的免疫抑制药物。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND/AIMS: To evaluate the efficacy, safety and tolerability of enteric-coated mycophenolate sodium (EC-MPS) in combination with low-dose corticosteroids compared with a monotherapy with low-dose corticosteroids in subjects with non-infectious intermediate uveitis (IU). METHODS: Open-label, prospective, controlled, randomised multicentre trial. Patients were randomised in a 1:1 ratio to either the treatment group (prednisolone plus EC-MPS) or control group (prednisolone monotherapy). Patients in the control group who relapsed within 6 months changed to the crossover group (prednisolone plus EC-MPS). Maximum treatment duration was 15 months. The primary endpoint was the time to first relapse in the treatment group and control group. RESULTS: Forty-one patients at eight sites were analysed. Twenty-two patients were allocated to the treatment group, with 19 patients in the control group. A first relapse occurred in 9 patients (40.9%) in the treatment group and 15 patients (78.9%) in the control group (p=0.03). The median time to the first relapse was >15 months for the treatment group and 2.8 months for the control group (p=0.07). The probability of relapse-free survival at month 15 was estimated to be 52.9% in the treatment group and 19.7% in the control group (p=0.01). 15 patients changed to the crossover group. Of these, only four patients developed a second relapse. No safety concerns arose during the trial. Only one patient had to discontinue EC-MPS due to increased liver enzymes. CONCLUSION: EC-MPS can be considered an effective and well-tolerated immunosuppressive drug to prevent relapses in patients with chronic IU. TRIAL REGISTRATION NUMBER: EUDRACT number: 2009-009998-10, Results.
引用
- Deuter CME, Engelmann K, Heiligenhaus A, et al. Enteric-coated mycophenolate sodium in the treatment of non-infectious intermediate uveitis: results of a prospective, controlled, randomised, open-label, early terminated multicentre trial. Br J Ophthalmol. 2017. PMID: 28903965. doi:10.1136/bjophthalmol-2017-310156
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。